India’s indigenously developed coronavirus vaccine Covaxin has been declared 77.8% effective against symptomatic COVID-19 infection in a study by The Lancet journal which also found it 65.2% effective against the more virulent Delta strain, although the later finding is based on preliminary data that still needs to be studied further.
The randomized trials with 24,419 participants aged 18-97 years held between November 2020 and May 2021 saw no deaths of adverse incidents related to the vaccine, the study says.
"Efficacy against any severity of COVID-19 with onset 14 days after the second vaccination was 77.8 per cent... Our preliminary analysis found an efficacy of 65.2 per cent against the Delta variant, but further investigations are necessary to confirm clinical efficacy against this variant and others” it states.
Now, both the WHO and Lancet have given their approval to Covaxin which can step up its export to other countries as well. The WHO's Strategic Advisory Group of Experts on Immunization approved Covaxin in two doses with a four weeks’ interval.
Latest Videos
